VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Go back to VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 6.20 +0.31 (5.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.89 | 52 Week High | $2.43 | |||
| Open | $5.87 | 52 Week Low | $1.05 | |||
| Day High | $6.31 | P/E | N/A | |||
| Day Low | $5.75 | EPS | $-1.79 | |||
| Volume | 1,574,254 | |||||
